Three-Year Safety and Efficacy of Vicriviroc, a CCR5 Antagonist, in HIV-1-Infected, Treatment-Experienced Patients

BACKGROUND: Vicriviroc, an investigational CCR5 antagonist, demonstrated short-term safety and antiretroviral activity. METHODS: Phase 2, double-blind, randomized study of vicriviroc in treatment-experienced subjects with CCR5-using HIV-1. Vicriviroc (5, 10 or 15 mg) or placebo was added to a failin...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Wilkin, Timothy J., Su, Zhaohui, Krambrink, Amy, Long, Jianmin, Greaves, Wayne, Gross, Robert, Hughes, Michael D., Flexner, Charles, Skolnik, Paul R., Coakley, Eoin, Godfrey, Catherine, Hirsch, Martin, Kuritzkes, Daniel R., Gulick, Roy M.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2010
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2917795/
https://ncbi.nlm.nih.gov/pubmed/20672447
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items